Fampridine
Lords · Question HL3467 · Tabled 14 Sep 2026 · Department of Health and Social Care · Official record
Answered 25 Sep 2026
Question
Asked by Lord Bowness
To ask His Majesty's Government whether funding is in place to meet the cost of ongoing treatment with Fampridine for patients with multiple sclerosis in England; and, if not, when will it be.
Answer
Answered by Baroness Merron, 25 Sep 2026
NHS England published a clinical commissioning policy in July 2026 recommending prolonged-release fampridine as a routine commissioning treatment option for adults in England with multiple sclerosis (MS) and associated walking impairment who meet the defi...